search
Back to results

A Study to Determine the Efficacy and Safety of Two Mometasone Dry Powder Inhalers in the Treatment of Asthma (Study P02524)

Primary Purpose

Asthma

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
MF
MF
Sponsored by
Organon and Co
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Must be >=18 years of age, of either gender & of any race.
  • Must have had a diagnosis of asthma for at least 6 months, characterized by recurrent episode of wheezing, breathlessness, chest tightness & coughing.
  • Baseline FEV1 must be >=55% and <=85% of predicted at the Screening Visit, when all restricted medications have been withheld for the specified intervals.
  • Must demonstrate evidence of an increase in absolute FEV1 of >=12%, with an absolute volume increase of at least 200 mL, after reversibility testing at the Screening Visit or documented in the patients chart reversibility up to 1 year previous to inclusion.
  • Must be free of any clinically significant disease (other than asthma), that would interfere with study evaluations.
  • Must be willing to give written informed consent and be able to adhere to dose & visit schedules.
  • Must agree to inform their own usual treating physician about their participation in the study.
  • Non-pregnant women of childbearing potential must be using a medically acceptable, adequate form of birth control. This includes: 1) hormonal contraceptive as prescribed by a physician (eg, oral combined, hormonal implant, depot injectable); 2) medically prescribed IUD; 3) condom in combination with a spermicide; 4) Monogamous relationship with a male partner who has had a vasectomy or is using a condom plus spermicide during the study. They must have started this birth control method at least 3 months prior to Screening (with the exception of condom in combination with a spermicide), & must agree to continue its use for the duration of the study. Women of childbearing potential who are not currently sexually active must agree and consent to using a double-barrier method should they become sexually active during the course of this study. Women who are surgically sterilized or are at least 1 year postmenopausal are considered not to be of childbearing potential. However, all female subjects must have a urine pregnancy test obtained at screening, prior to initiation of treatment, & at the end of the trial, which must be negative.
  • Subjects who did not use the following medication prior to inclusion:

    • Beta 2 agonist short-acting (inhaled, oral)(12 Hours)
    • Beta 2 agonist long-acting (inhaled)(48 Hours)
    • Ipratropium bromide (12 hours)
    • Cromolyn sodium, nedocromil (7 days)
    • Astemizole (3 months)
    • Cetotifeno (3 months)
    • Another investigational drug (1 month)
    • Theophyline (2 weeks)
    • Antihistamines (7 days)
    • Anticholinergics (7 days)
    • Leukotriene modifiers (2 weeks)
    • Oral decongestant long-acting (72 hours)
    • Oral decongestant short-acting (24 hours)
    • Oral corticosteroids (1 month)
    • Injected corticosteroids (3 months)
    • Inhaled corticosteroids (24 hours)
  • Baseline portable Peak Expiratory Flow at the Screening Visit must be >50% of predicted. The best value out of 3 must be considered.

Exclusion Criteria:

  • Women who are pregnant, breast-feeding, or are pre-menarcheal.
  • Have used any investigational drug within the last 30 days or who have ever been treated with any investigational antibody for asthma or rhinitis.
  • Are receiving escalating doses of immunotherapy, oral immunotherapy or short course (rush) immunotherapy.
  • No subject participating in this study may participate in this same study at another investigational site or in any other investigational study at the same time.
  • Must not be randomized into the study more than once.
  • Subjects with the following clinical conditions/demography:

    • Allergic to corticosteroids or beta-agonists.
    • Required hospitalization for asthma control within the previous 3 months.
    • Required ventilator support for respiratory failure secondary to their asthma within the last 5 years.
    • Treated in the ER (for a severe asthma exacerbation), or admitted to the hospital for management of airway obstruction, on 2 or more occasions within the last 6 months.
    • Clinical evidence of emphysema, chronic bronchitis, bronchiectasis, or cystic fibrosis.
    • Significant history of renal, hepatic, cardiovascular, metabolic, neurologic, hematological, respiratory, gastrointestinal, cerebrovascular, or other significant medical illness or disorder which, in the judgment of the investigator, could have interfered with the study, or required treatment which might have interfered with the study.
    • Requiring the use of >12 puffs per day of Salbutamol on any 2 consecutive days between study visits.
    • Experienced upper or lower respiratory tract infection within the previous 2 weeks prior to enrollment.
    • Clinically relevant abnormal baseline vital sign.
    • Clinically significant abnormalities on chest x-ray at the Screening Visit or within the previous 6 months.
    • Evidence of clinically significant oropharyngeal candidiasis.
    • Smokers, or ex-smokers who are smoking or have smoked at least 20 years/pack or subjects who are smoking in the last 6 months.
    • Known to be HIV positive.
    • Known to be illicit drug abusers.
    • HPA axis disturbances.
    • Showing any clinical condition considered to be severe.
    • Severe airflow obstruction showing to be life-threatening.
    • Baseline FEV1 <55% of the predicted normal.
    • Uncontrolled hypertension.
    • Suspected pneumonia, pneumothorax, pneumomediastinum, pulmonary TB, alpha-1 anti-trypsin deficiency, lung mycosis or pulmonary cystic fibrosis.
    • History of thoracic surgery or any previous malignancy of the lung,
    • Significant heart disease,
    • Receiving beta-adrenergic blocking agents.
  • Presenting baseline portable peak expiratory flow at the Screening Visit <=50% of predicted. The best value out of 3 must be considered.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Experimental

    Arm Label

    Group 1

    Group 2

    Arm Description

    Outcomes

    Primary Outcome Measures

    The assessment of efficacy will be done by spirometry, determining the difference in FEV1 and PEFR measured by spirometry on baseline, 7, 14, 28, 42 and 56 days after initiation of MF dry powder inhaler (DPI) therapy.
    To determine the number of puffs/day of rescue medication (Salbutamol).

    Secondary Outcome Measures

    To compare the PEFR daily measurements obtained by Peak flow Meter used by subjects at home.
    To compare the daily scores for asthma symptoms and sleep quality.
    To compare the evaluation of response to therapy made by the investigator at each visit compared to the Baseline visit.
    To determine and compare the safety (HPA axis evaluation) of both treatments using 400 μg MF DPI once daily in adult subjects with asthma.
    To determine and compare the safety (clinical laboratory measurements) of both treatments using 400 μg MF DPI once daily in adult subjects with asthma.
    To determine and compare the tolerability (adverse events) of both treatments using 400 μg MF DPI once daily in adult subjects with asthma.

    Full Information

    First Posted
    January 6, 2009
    Last Updated
    February 1, 2022
    Sponsor
    Organon and Co
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00817817
    Brief Title
    A Study to Determine the Efficacy and Safety of Two Mometasone Dry Powder Inhalers in the Treatment of Asthma (Study P02524)
    Official Title
    An Open-Label, Comparative, Randomized, Parallel, Multicenter Study to Determine the Efficacy and Safety of Two Dry Powder Inhalers (DPIs) Used for the Application of Mometasone in the Treatment of Asthma
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2022
    Overall Recruitment Status
    Completed
    Study Start Date
    October 1, 2002 (Actual)
    Primary Completion Date
    May 1, 2003 (Actual)
    Study Completion Date
    May 1, 2003 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Organon and Co

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This is an open-label, comparative, randomized, parallel, multicenter study in asthmatics to determine whether the administration of dry powder inhaled mometasone furoate (MF) 400 μg in a monodose capsule device would be comparable to administration of powder inhaled MF 400 μg in a multidose device.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Asthma

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    93 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Group 1
    Arm Type
    Experimental
    Arm Title
    Group 2
    Arm Type
    Experimental
    Intervention Type
    Device
    Intervention Name(s)
    MF
    Other Intervention Name(s)
    Asmanex, SCH 32088
    Intervention Description
    One evening dose of dry powder inhaled MF 400 μg (Multidose device).
    Intervention Type
    Device
    Intervention Name(s)
    MF
    Other Intervention Name(s)
    Asmanex, SCH 32088
    Intervention Description
    One evening dose of dry powder inhaled 400 μg (400 μg capsules - Monodose).
    Primary Outcome Measure Information:
    Title
    The assessment of efficacy will be done by spirometry, determining the difference in FEV1 and PEFR measured by spirometry on baseline, 7, 14, 28, 42 and 56 days after initiation of MF dry powder inhaler (DPI) therapy.
    Time Frame
    Baseline, 7, 14, 28, 42, and 56 days after initiation of MF DPI therapy.
    Title
    To determine the number of puffs/day of rescue medication (Salbutamol).
    Time Frame
    Daily
    Secondary Outcome Measure Information:
    Title
    To compare the PEFR daily measurements obtained by Peak flow Meter used by subjects at home.
    Time Frame
    Daily
    Title
    To compare the daily scores for asthma symptoms and sleep quality.
    Time Frame
    Every morning
    Title
    To compare the evaluation of response to therapy made by the investigator at each visit compared to the Baseline visit.
    Time Frame
    Visits 2 to 6.
    Title
    To determine and compare the safety (HPA axis evaluation) of both treatments using 400 μg MF DPI once daily in adult subjects with asthma.
    Time Frame
    Visits 2 to 6
    Title
    To determine and compare the safety (clinical laboratory measurements) of both treatments using 400 μg MF DPI once daily in adult subjects with asthma.
    Time Frame
    Visit 6
    Title
    To determine and compare the tolerability (adverse events) of both treatments using 400 μg MF DPI once daily in adult subjects with asthma.
    Time Frame
    Visits 2 to 6.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Must be >=18 years of age, of either gender & of any race. Must have had a diagnosis of asthma for at least 6 months, characterized by recurrent episode of wheezing, breathlessness, chest tightness & coughing. Baseline FEV1 must be >=55% and <=85% of predicted at the Screening Visit, when all restricted medications have been withheld for the specified intervals. Must demonstrate evidence of an increase in absolute FEV1 of >=12%, with an absolute volume increase of at least 200 mL, after reversibility testing at the Screening Visit or documented in the patients chart reversibility up to 1 year previous to inclusion. Must be free of any clinically significant disease (other than asthma), that would interfere with study evaluations. Must be willing to give written informed consent and be able to adhere to dose & visit schedules. Must agree to inform their own usual treating physician about their participation in the study. Non-pregnant women of childbearing potential must be using a medically acceptable, adequate form of birth control. This includes: 1) hormonal contraceptive as prescribed by a physician (eg, oral combined, hormonal implant, depot injectable); 2) medically prescribed IUD; 3) condom in combination with a spermicide; 4) Monogamous relationship with a male partner who has had a vasectomy or is using a condom plus spermicide during the study. They must have started this birth control method at least 3 months prior to Screening (with the exception of condom in combination with a spermicide), & must agree to continue its use for the duration of the study. Women of childbearing potential who are not currently sexually active must agree and consent to using a double-barrier method should they become sexually active during the course of this study. Women who are surgically sterilized or are at least 1 year postmenopausal are considered not to be of childbearing potential. However, all female subjects must have a urine pregnancy test obtained at screening, prior to initiation of treatment, & at the end of the trial, which must be negative. Subjects who did not use the following medication prior to inclusion: Beta 2 agonist short-acting (inhaled, oral)(12 Hours) Beta 2 agonist long-acting (inhaled)(48 Hours) Ipratropium bromide (12 hours) Cromolyn sodium, nedocromil (7 days) Astemizole (3 months) Cetotifeno (3 months) Another investigational drug (1 month) Theophyline (2 weeks) Antihistamines (7 days) Anticholinergics (7 days) Leukotriene modifiers (2 weeks) Oral decongestant long-acting (72 hours) Oral decongestant short-acting (24 hours) Oral corticosteroids (1 month) Injected corticosteroids (3 months) Inhaled corticosteroids (24 hours) Baseline portable Peak Expiratory Flow at the Screening Visit must be >50% of predicted. The best value out of 3 must be considered. Exclusion Criteria: Women who are pregnant, breast-feeding, or are pre-menarcheal. Have used any investigational drug within the last 30 days or who have ever been treated with any investigational antibody for asthma or rhinitis. Are receiving escalating doses of immunotherapy, oral immunotherapy or short course (rush) immunotherapy. No subject participating in this study may participate in this same study at another investigational site or in any other investigational study at the same time. Must not be randomized into the study more than once. Subjects with the following clinical conditions/demography: Allergic to corticosteroids or beta-agonists. Required hospitalization for asthma control within the previous 3 months. Required ventilator support for respiratory failure secondary to their asthma within the last 5 years. Treated in the ER (for a severe asthma exacerbation), or admitted to the hospital for management of airway obstruction, on 2 or more occasions within the last 6 months. Clinical evidence of emphysema, chronic bronchitis, bronchiectasis, or cystic fibrosis. Significant history of renal, hepatic, cardiovascular, metabolic, neurologic, hematological, respiratory, gastrointestinal, cerebrovascular, or other significant medical illness or disorder which, in the judgment of the investigator, could have interfered with the study, or required treatment which might have interfered with the study. Requiring the use of >12 puffs per day of Salbutamol on any 2 consecutive days between study visits. Experienced upper or lower respiratory tract infection within the previous 2 weeks prior to enrollment. Clinically relevant abnormal baseline vital sign. Clinically significant abnormalities on chest x-ray at the Screening Visit or within the previous 6 months. Evidence of clinically significant oropharyngeal candidiasis. Smokers, or ex-smokers who are smoking or have smoked at least 20 years/pack or subjects who are smoking in the last 6 months. Known to be HIV positive. Known to be illicit drug abusers. HPA axis disturbances. Showing any clinical condition considered to be severe. Severe airflow obstruction showing to be life-threatening. Baseline FEV1 <55% of the predicted normal. Uncontrolled hypertension. Suspected pneumonia, pneumothorax, pneumomediastinum, pulmonary TB, alpha-1 anti-trypsin deficiency, lung mycosis or pulmonary cystic fibrosis. History of thoracic surgery or any previous malignancy of the lung, Significant heart disease, Receiving beta-adrenergic blocking agents. Presenting baseline portable peak expiratory flow at the Screening Visit <=50% of predicted. The best value out of 3 must be considered.

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    20835586
    Citation
    Pereira CA, Vianna FF, Cukier A, Stelmach R, Oliveira JC, Carvalho EV, Gomes EP, Mayo SV, Chibante AM, Domingues CP. Efficacy and safety of two dry-powder inhalers for the administration of mometasone furoate in asthma patients. J Bras Pneumol. 2010 Jul-Aug;36(4):410-6. doi: 10.1590/s1806-37132010000400004. English, Portuguese.
    Results Reference
    result
    Available IPD and Supporting Information:
    Available IPD/Information Type
    CSR Synopsis
    Available IPD/Information URL
    http://www.merck.com/clinical-trials/policies-perspectives.html

    Learn more about this trial

    A Study to Determine the Efficacy and Safety of Two Mometasone Dry Powder Inhalers in the Treatment of Asthma (Study P02524)

    We'll reach out to this number within 24 hrs